Navega Therapeutics
Navega Therapeutics: Innovating non-addictive, specific, long-lasting, non-permanent gene therapy for pain.
Founded
2018Navega Therapeutics: Innovating non-addictive, specific, long-lasting, non-permanent gene therapy for pain.
Founded with a mission to revolutionize pain management, Navega Therapeutics is pioneering non-addictive, highly specific, and long-lasting gene therapies. The company leverages advanced zinc-finger and CRISPR-based epigenome regulation technologies to develop non-permanent gene therapies that target pain. Navega Therapeutics aims to provide innovative solutions that address the opioid crisis by offering safer alternatives for chronic pain sufferers.
Navega Therapeutics has garnered attention for its cutting-edge approach and has attracted notable investors and advisors in the biotech industry. The company's achievements include securing patents for its novel gene therapy techniques and advancing preclinical studies that demonstrate the efficacy and safety of their treatments. Navega Therapeutics is poised to make a significant impact on the field of pain management and the broader healthcare landscape by providing groundbreaking alternatives to traditional pain relief methods.
Companies similar to Navega Therapeutics include Opsin Biotherapeutics, Latigo Biotherapeutics, Regel Therapeutics and Regulonix Holding.
Navega Therapeutics was founded in 2018.
Navega Therapeutics' headquarters is located in San Diego, CA, US.
Navega Therapeutics' most recent funding round was for $1.2M (USD) in April 2022.
As of Apr 1, 2022, Navega Therapeutics has disclosed funding of $7.8M (USD). Undisclosed round amounts are excluded.
Navega Therapeutics has 10 employees as of Feb 4, 2024.
Regulonix Holding
